Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

In closing, this is a very exciting time for Amarantus. We just completed our first institutional capital raise and have attracted Big Pharma talent to our Advisory Board. We have data coming shortly on our MANF Parkinson’s program and expect additional corporate milestones will be reached in the coming weeks. As we achieve these milestones, we believe we will be in a good position to up-list to a national exchange. Most importantly, we are looking to bring hope to millions of patients and their families who suffer from the debilitating diseases MANF has the potential to treat. We strongly believe this strategy will build long-term shareholder value.

http://www.thechairmansblog.com/gerald-commissiong/2012-12/manf-arresting-cell-death-in-parkinsons-disease-traumatic-brain-injury-cardiac-ischemia-and-more.html